Your browser is no longer supported. Please, upgrade your browser.
Settings
FATE Fate Therapeutics, Inc. daily Stock Chart
FATE [NASD]
Fate Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.85 Insider Own0.90% Shs Outstand86.89M Perf Week14.90%
Market Cap4.71B Forward P/E- EPS next Y-1.73 Insider Trans154.17% Shs Float85.69M Perf Month20.38%
Income-148.60M PEG- EPS next Q-0.38 Inst Own- Short Float16.74% Perf Quarter64.88%
Sales18.30M P/S257.15 EPS this Y-21.50% Inst Trans1.36% Short Ratio16.09 Perf Half Y76.16%
Book/sh4.88 P/B11.71 EPS next Y0.60% ROA-31.20% Target Price51.13 Perf Year280.87%
Cash/sh5.93 P/C9.63 EPS next 5Y- ROE-43.60% 52W Range13.26 - 57.15 Perf YTD191.93%
Dividend- P/FCF- EPS past 5Y-2.60% ROI-41.10% 52W High1.35% Beta1.69
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low336.80% ATR3.08
Employees178 Current Ratio9.20 Sales Q/Q216.70% Oper. Margin- RSI (14)69.34 Volatility5.35% 6.70%
OptionableYes Debt/Eq0.00 EPS Q/Q-69.90% Profit Margin- Rel Volume0.39 Prev Close57.13
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume891.45K Price57.92
Recom1.70 SMA2014.61% SMA5025.51% SMA20067.85% Volume302,579 Change1.38%
May-13-20Initiated H.C. Wainwright Buy $42
Mar-04-20Initiated Barclays Overweight $40
Jan-09-20Downgrade BMO Capital Markets Outperform → Market Perform $22
Dec-30-19Reiterated Mizuho Buy $27 → $33
Dec-09-19Upgrade Wells Fargo Market Perform → Outperform
Nov-12-19Initiated SunTrust Buy $25
Nov-06-19Downgrade Wells Fargo Outperform → Market Perform
Oct-01-19Initiated Stifel Buy $27
Aug-09-19Initiated BTIG Research Buy $27
Jul-22-19Initiated Cantor Fitzgerald Overweight
Jul-12-19Initiated Oppenheimer Outperform $27
Jun-13-19Initiated Mizuho Buy
Jun-07-19Initiated ROTH Capital Neutral $20
May-31-19Initiated Guggenheim Buy
May-24-19Resumed Citigroup Buy $26
Mar-28-19Initiated SVB Leerink Outperform $20
Jan-03-19Downgrade Stephens Overweight → Equal-Weight
Nov-05-18Initiated Jefferies Buy
Aug-01-18Initiated Citigroup Buy $20
Mar-06-18Downgrade H.C. Wainwright Buy → Neutral $12
Nov-12-20 04:01PM  
Nov-10-20 05:54AM  
Nov-07-20 02:00AM  
Nov-05-20 06:05PM  
04:01PM  
03:45PM  
08:00AM  
Nov-03-20 09:15AM  
Nov-02-20 07:00AM  
Oct-15-20 08:00AM  
Sep-30-20 08:00AM  
Sep-11-20 10:11AM  
Sep-04-20 08:00AM  
Aug-19-20 08:00AM  
Aug-11-20 08:19AM  
08:00AM  
Aug-05-20 05:55PM  
04:01PM  
Aug-04-20 04:01PM  
Jul-29-20 04:01PM  
Jul-28-20 12:32PM  
Jul-26-20 07:40AM  
Jul-21-20 08:11AM  
Jul-16-20 11:06AM  
Jul-14-20 08:00AM  
Jul-10-20 10:18AM  
Jul-09-20 08:00AM  
Jun-15-20 10:50PM  
01:44PM  
Jun-13-20 07:50AM  
Jun-11-20 04:01PM  
Jun-09-20 05:29PM  
02:10PM  
12:49AM  
Jun-08-20 04:01PM  
May-20-20 08:00AM  
May-15-20 06:18AM  
May-12-20 04:30PM  
01:40PM  
May-11-20 05:15PM  
04:01PM  
May-08-20 08:46AM  
May-05-20 09:18PM  
04:01PM  
May-04-20 04:01PM  
09:38AM  
Apr-30-20 08:33AM  
Apr-29-20 07:11AM  
Apr-28-20 04:30PM  
12:33PM  
Apr-14-20 09:13AM  
Apr-10-20 12:00PM  
Apr-08-20 11:30AM  
10:05AM  
10:04AM  
Apr-06-20 09:08AM  
Apr-04-20 09:07AM  
Apr-03-20 06:34PM  
04:20PM  
10:57AM  
07:36AM  
Apr-02-20 04:46PM  
04:45PM  
Mar-25-20 09:04AM  
Mar-17-20 10:24AM  
Mar-02-20 05:15PM  
04:01PM  
Feb-29-20 02:52PM  
Feb-26-20 08:00AM  
Feb-25-20 12:30PM  
Feb-07-20 08:00AM  
Feb-05-20 11:52AM  
Jan-16-20 06:15AM  
Jan-13-20 08:00AM  
Jan-03-20 10:44AM  
Dec-13-19 02:18PM  
Dec-11-19 09:41AM  
Dec-10-19 09:52AM  
09:48AM  
09:07AM  
Dec-09-19 04:19PM  
02:16PM  
11:04AM  
Dec-08-19 07:28PM  
10:39AM  
Dec-07-19 08:40AM  
Dec-02-19 05:49AM  
Nov-27-19 04:01PM  
Nov-14-19 04:01PM  
Nov-06-19 09:01AM  
Nov-05-19 07:25PM  
04:05PM  
Oct-29-19 04:01PM  
Oct-28-19 07:44PM  
Oct-18-19 08:12AM  
05:57AM  
Oct-01-19 01:48PM  
Sep-30-19 08:00AM  
Sep-18-19 04:01PM  
Sep-12-19 07:38AM  
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shoemaker Daniel DChief Scientific OfficerNov 16Sale51.8325,0001,295,74693,091Nov 16 05:12 PM
Wolchko J ScottPresident and CEONov 13Option Exercise5.7330,000172,008430,123Nov 16 04:02 PM
Wolchko J ScottPresident and CEONov 13Sale51.0330,0001,530,900419,969Nov 16 04:02 PM
Wolchko J ScottPresident and CEONov 12Option Exercise2.7330,00081,900449,969Nov 16 04:02 PM
Wolchko J ScottPresident and CEONov 12Sale52.7230,0001,581,524419,969Nov 16 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 05Option Exercise2.8219,28254,340118,800Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 05Sale50.6319,282976,25299,518Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 04Option Exercise2.7351,519140,647151,037Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryNov 04Sale50.4151,5192,597,14099,518Nov 06 04:02 PM
TAHL CINDYGeneral Counsel and SecretaryOct 16Option Exercise2.7329,19979,713128,717Oct 20 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryOct 16Sale50.2529,1991,467,21299,518Oct 20 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryOct 01Option Exercise2.7335,00095,550134,518Oct 02 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryOct 01Sale40.7435,0001,426,06599,518Oct 02 04:01 PM
Valamehr BahramChief Development OfficerSep 14Option Exercise2.7525,00068,778112,211Sep 16 04:02 PM
Shoemaker Daniel DChief Scientific OfficerSep 14Sale36.3025,000907,540118,091Sep 16 04:01 PM
Valamehr BahramChief Development OfficerSep 14Sale36.2825,000907,02487,211Sep 16 04:02 PM
Redmile Group, LLCDirectorJun 11Buy28.311,412,92839,999,99212,629,737Jun 17 08:25 PM
RASTETTER WILLIAM HDirectorMar 30Option Exercise1.3728,46138,99228,461Mar 31 04:01 PM
Valamehr BahramChief Development OfficerFeb 03Option Exercise1.691,1531,94987,211Feb 04 04:01 PM
Wolchko J ScottPresident and CEOJan 30Option Exercise2.7025,00067,500444,969Feb 03 04:01 PM
Wolchko J ScottPresident and CEOJan 30Sale25.4525,000636,303419,969Feb 03 04:01 PM
Valamehr BahramChief Development OfficerJan 08Sale20.695,700117,94786,058Jan 10 04:03 PM
TAHL CINDYGeneral Counsel and SecretaryJan 08Sale20.725,700118,08599,518Jan 10 04:02 PM
Shoemaker Daniel DChief Scientific OfficerJan 08Sale20.705,700117,986143,091Jan 10 04:01 PM
Shoemaker Daniel DChief Scientific OfficerDec 30Option Exercise2.9025,00072,500148,791Jan 02 04:01 PM
Shoemaker Daniel DChief Scientific OfficerDec 30Sale19.5025,000487,427123,791Jan 02 04:01 PM
Wolchko J ScottPresident and CEODec 20Option Exercise2.7025,00067,500378,969Dec 23 04:02 PM
Wolchko J ScottPresident and CEODec 20Sale20.1725,000504,158353,969Dec 23 04:02 PM
Wolchko J ScottPresident and CEODec 19Option Exercise2.7025,00067,500378,969Dec 23 04:02 PM
Wolchko J ScottPresident and CEODec 19Sale20.0825,000501,898353,969Dec 23 04:02 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.